Unfortunately, it is difficult to foresee the widespread introduction of mental health services in substance abuse treatment settings for two primary reasons. First, treatment protocols for patients with both addictive and mental disorders are still working their way through the research and translation-to-practice stages. The only protocols for comorbid drug addiction and mental disorders selected for CTN testing, translation, and dissemination have been for adolescent substance abusers with attention-deficit hyperactivity disorder (ADHD) and smokers with ADHD (osmotic-release methylphenidate). Second, the public reimbursement systems for treatment of addictions and mental disorders are distinct, and payment models must be developed for pharmacologic treatment of persons with comorbid disorders.